A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Phase of Trial: Phase III
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Ozanimod (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation; Celgene International SARL
- 30 Nov 2018 Status changed from not yet recruiting to recruiting.
- 03 Jul 2018 Planned End Date changed from 31 Dec 2022 to 30 Dec 2022.
- 03 Jul 2018 Planned primary completion date changed from 31 Dec 2022 to 30 Dec 2022.